Capricor Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Capricor Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 95% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 85% of its market value (net cash). Higher than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-8.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 50% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +611%In 3 years sales changed by -100% while total assets changed by +611%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-345.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 95% of Healthcare companies in United States.
Cash Cushion Ratio
+85%Cash, after subtracting all debt, equals 85% of its market value (net cash).
Higher than 86% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Capricor Therapeutics, Inc. made a loss over the last year. Capricor Therapeutics, Inc. owes $0.33 for every $1 it owns. Capricor Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCapricor Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.45The share price is 1.45 times Capricor Therapeutics, Inc.'s book value per share, lower than 69% of Healthcare companies in United States.
Market cap
$356 MThe total market value of all of Capricor Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 50% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$246 MWhat Capricor Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.24Net worth divided by the number of shares. The share price of $6.13 is 1.4 times this, which is the P/B above.
Return on equity (ROE)
-73.7%Capricor Therapeutics, Inc. lost 73.7% of its shareholders' money over the last year, lower than 62% of Healthcare companies in United States.
Owes vs Owns
0.33×Capricor Therapeutics, Inc. owes $0.33 for every $1 it owns (low), lower than 57% of Healthcare companies in United States.
Dividend yield
NoneCapricor Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossCapricor Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredCapricor Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCapricor Therapeutics, Inc. held $304 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Capricor Therapeutics, Inc.: $356 M ÷ $246 M (30 Jun 2026) = 1.4.
What is Capricor Therapeutics, Inc.'s return on equity?
Capricor Therapeutics, Inc. lost 73.7% of its shareholders' money over the last year, lower than 62% of Healthcare companies in United States.
How much does Capricor Therapeutics, Inc. owe compared with what it owns?
Capricor Therapeutics, Inc. owes $0.33 for every $1 it owns (low), lower than 57% of Healthcare companies in United States.
Does Capricor Therapeutics, Inc. pay a dividend?
No. Capricor Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.